| 83 INVESTMENT GROUP INCOME FUND | |||||||
| SCHEDULE OF INVESTMENTS (Unaudited) | |||||||
| June 30, 2026 | |||||||
| Shares | Fair Value | ||||||
| CLOSED-END FUNDS(f) — 3.8% | |||||||
| FIXED INCOME - 3.8% | |||||||
| 1,053,352 | Blue Owl Alternative Credit Fund | $ 10,512,453 | |||||
|
| |||||||
| TOTAL CLOSED-END FUNDS (Cost $10,245,204) |
10,512,453 | ||||||
| OPEN-END FUNDS(f) — 1.0% | |||||||
| FIXED INCOME - 1.0% | |||||||
| 85,229 | Angel Oak UltraShort Income Fund, Institutional Class | 840,360 | |||||
| 100,581 | CrossingBridge Ultra-Short Duration Fund, Institutional Class | 1,000,597 | |||||
| 121,876 | RiverPark Strategic Income Fund, Institutional Class | 1,033,362 | |||||
|
2,874,319 | |||||||
| TOTAL OPEN-END FUNDS (Cost $2,898,458) |
2,874,319 | ||||||
| PRIVATE INVESTMENT FUNDS(a)(b)(f) — 97.9% | |||||||
| FINANCIALS - 97.9% | |||||||
| N/A | Callodine Perpetual ABL Fund L.P. | 32,354,259 | |||||
| N/A | Clear Haven Investment Fund, L.P (Credit Opportunities Fund III Series) | 10,969,054 | |||||
| N/A | Clear Haven Ultra Short IG Bond Fund, L.P. | 8,557,987 | |||||
| N/A | Colbeck Strategic Lending Fund L.P. | 7,795,705 | |||||
| N/A | Equal Access Justice Fund L.P. | 27,040,924 | |||||
| N/A | Evolution Credit Partners Trade Finance, L.P. | 14,144,605 | |||||
| N/A | Felicitas Liquidity Solutions Fund L.P. | 7,865,821 | |||||
| N/A | MEP Evergreen Fund, L.P. | 8,090,994 | |||||
| N/A | MRP Evergreen Income Fund, L.P. | 30,745,279 | |||||
| N/A | Proterra Credit Fund 2 (Feeder), L.P. | 9,864,085 | |||||
| N/A | Proterra Credit Partners, L.P. | 17,666,638 | |||||
| N/A | Rivonia Road Fund L.P. | 6,657,428 | |||||
| N/A | SC 2025 Opportunities Holdings II, L.P. | 4,896,657 | |||||
| N/A | Symbiotic Capital Life Science Credit Fund, L.P. | 8,558,508 | |||||
| N/A | WhiteHawk Evergreen Fund, L.P. | 75,004,623 | |||||
| TOTAL PRIVATE INVESTMENT FUNDS (Cost $260,732,220) |
270,212,567 | ||||||
| 83 INVESTMENT GROUP INCOME FUND | |||||||
| SCHEDULE OF INVESTMENTS (Unaudited) (Continued) | |||||||
| June 30, 2026 | |||||||
| Principal Amount ($) | Coupon Rate (%) | Maturity | Fair Value | ||||
| LOAN PARTICIPATIONS(b)(f) — 3.4% | |||||||
| CONSUMER DISCRETIONARY — 0.7% | |||||||
| 2,000,000 |
Penney Holdings LLC/Catalyst Brands (WhiteHawk Evergreen Fund, L.P.) SOFR + 8.13% |
11.7900 | 09/19/30 | $ 2,000,000 | |||
| 1,880,611 |
HEALTH CARE — 0.7% Nephron Pharmaceuticals LLC (WhiteHawk Evergreen Fund, L.P.) SOFR + 9.20% |
12.8600 | 12/30/27 | 1,842,999 | |||
| INDUSTRIALS — 1.5% | |||||||
| 1,964,167 |
C3 Rentals, Inc. (WhiteHawk Evergreen Fund, L.P.) SOFR + 8.00% |
12.0000 | 04/22/27 | 1,964,167 | |||
| 1,997,568 |
West Side Transport, Inc. (WhiteHawk Evergreen Fund, L.P.) SOFR + 9.00% |
13.0000 | 08/02/27 | 2,097,446 | |||
| 4,061,613 | |||||||
| TECHNOLOGY — 0.5% | |||||||
| 1,611,424 |
Boxlight Corporation (WhiteHawk Evergreen Fund, L.P.) SOFR + 10.75% |
10.7500 | 04/01/27 | 1,329,425 | |||
| TOTAL LOAN PARTICIPATIONS (Cost $9,398,926) |
9,234,037 | ||||||
| Shares | Expiration Date | Exercise Price | |||||
| WARRANT — 0.0%(b)(c)(e)(f) | |||||||
| HEALTH CARE — 0.0% | |||||||
| 3 | Nephron Pharmaceuticals LLC | N/A | $0.01 | 19,098 | |||
| TOTAL WARRANT (Cost $22,548) | 19,098 | ||||||
| SHORT-TERM INVESTMENTS — 0.3% | |||||||
| MONEY MARKET FUNDS - 0.3% | |||||||
| 777,952 | First American Government Obligations Fund, Class X, 3.56% (Cost $777,952)(d)(f) | 777,952 | |||||
|
| |||||||
| TOTAL INVESTMENTS - 106.4% (Cost $284,075,308) | 293,630,426 | ||||||
| LIABILITIES IN EXCESS OF OTHER ASSETS – (6.4)% |
(17,657,946) | ||||||
| NET ASSETS - 100.0% |
$ 275,972,480 | ||||||
|
|
|||||||
| 83 INVESTMENT GROUP INCOME FUND |
| SCHEDULE OF INVESTMENTS (Unaudited) (Continued) |
| June 30, 2026 |
| LLC | - Limited Liability Company |
| L.P. | - Limited Partnership |
| N/A | - Not applicable |
| SOFR | - Secured Overnight Financing Rate |
| (a) | The investments held by the Fund do not issue shares. |
| (b) |
Restricted Security. Investments generally issued in private placement transactions and as such generally restricted as to resale. Each investment may have been purchased on various dates and for different amounts. Total fair value of restricted investments as of June 30, 2026 was $279,465,702 or 101.3% of net assets. As of June 30, 2026, the aggregate cost was $270,153,694. Additional details are as follows.
|
| Investment | Date of first purchase | Cost | ||
| Boxlight Corporation (loan participation) | 8/1/2024 | $ 1,614,798 | ||
| C3 Rentals, Inc. (loan participation) | 8/1/2024 | 1,958,291 | ||
| Callodine Perpetual ABL Fund, L.P. | 10/16/2024 | 33,250,000 | ||
| Clear Haven Investment Fund, L.P (Credit Opportunities Fund III Series) | 10/1/2025 | 9,950,199 | ||
| Clear Haven Ultra Short IG Bond Fund, L.P. | 7/2/2025 | 8,000,000 | ||
| Colbeck Strategic Lending Fund L.P. | 1/5/2026 | 7,798,511 | ||
| Equal Access Justice Fund L.P. | 5/1/2025 | 25,000,000 | ||
| Evolution Credit Partners | 9/2/2025 | 14,820,500 | ||
| Felicitas Liquidity Solutions Fund L.P. | 2/6/2026 | 7,176,908 | ||
| MEP Evergreen Fund, L.P. | 1/31/2025 | 30,000,000 | ||
| MRP Evergreen Income Fund, L.P. | 10/17/2025 | 7,852,961 | ||
| Nephron Pharmaceuticals LLC (loan participation) | 2/28/2025 | 1,855,834 | ||
| Nephron Pharmaceuticals LLC (warrant) | 2/28/2025 | 22,548 | ||
| Penney Holdings LLC/Catalyst Brands (loan participation) | 10/1/2025 | 1,980,202 | ||
| Proterra Credit Fund 2 (Feeder), L.P. | 4/1/2024 | 9,875,952 | ||
| Proterra Credit Partners, L.P. | 1/30/2026 | 17,000,000 | ||
| Rivonia Road Fund L.P. | 4/4/2025 | 6,000,000 | ||
| SC 2025 Opportunities Holdings II, L.P. | 5/8/2026 | 4,975,000 | ||
| Symbiotic Capital Life Science Credit Fund, L.P. | 8/9/2024 | 8,032,189 | ||
| West Side Transport, Inc. (loan participation) | 10/15/2024 | 1,989,801 | ||
| WhiteHawk Evergreen Fund, L.P. | 5/1/2024 | 71,000,000 |
| (c) | Percentage rounds to less than 0.1%. |
| (d) | Rate disclosed is the seven day effective yield as of June 30, 2026. |
| (e) | Non-income producing security. |
| (f) | Security pledged as collateral for line of credit. |